The use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis.

Activator of thyroid and retinoid receptor increases sorafenib resistance in hepatocellular carcinoma by facilitating the Warburg effect

“…Sorafenib is currently the main drug in the treatment of patients with advanced HCC and resistance occurs frequently 21‐24 . Our study established ACTR as a glycolytic inducer in regulating sorafenib resistance in vitro and in vivo.…”

Guidelines Insights: Hepatobiliary Cancers, Version 2.2019

“…The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. 1 Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 2 Memorial Sloan Kettering Cancer Center; 3 University of Wisconsin Carbone Cancer Center; 4 Dana-Farber/Brigham and Women's Cancer Center; 5 Mayo Clinic Cancer Center; 6 Moffitt Cancer Center; 7 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 8 Fred & Pamela Buffett Cancer Center; 9 Vanderbilt-Ingram Cancer Center; 10 Stanford Cancer Institute; 11 The Ohio State University Comprehensive Cancer Center -James Cancer Hospital and Solove Research Institute; 12 Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 13 Roswell Park Comprehensive Cancer Center; 14 University of Alabama at Birmingham Comprehensive Cancer Center; 15 Fox Chase Cancer Center; 16 UCSF Helen Diller Family Comprehensive Cancer Center; 17 Huntsman Cancer Institute at the University of Utah; 18 Duke Cancer Institute; 19 University of Washington/ Seattle Cancer Care Alliance; 20 University of Michigan Rogel Cancer Center; 21 University of Colorado Cancer Center; 22 UC San Diego Moores Cancer Center; 23 City of Hope National Medical Center; 24 Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; 25 Yale Cancer Center/Smilow Cancer Hospital;…”

“…16 Other investigators have also reported lower median OS for patients with C-P class B liver function. [17][18][19][20][21] In the GIDEON registry, the safety profile of sorafenib was generally similar for C-P classes A and B, although OS was shorter in patients with C-P class B liver function. 20 In the final analysis of the trial, in the intent-to-treat population (n53,213), median OS was 13.6 months for the C-P class A group compared with 5.2 months for the C-P class B group 22 ; time to progression (TTP) was, however, similar for the 2 groups (4.7 and 4.4 months, respectively).…”

Combinations of single nucleotide polymorphisms WWOX‐rs13338697, GALNT14‐rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma

“…Sorafenib is currently recommended as the first‐line therapy for advanced HCCs, based on two phase III randomized controlled trials . However, in HCC patients using sorafenib, a trend toward worse OS with CP class B comparing to CP class A patients was conceivable: the median was 6.1, 5.4 and 2.7 months among CP class A, CP class B (score 7) and CP class B (scores 8 and 9) patients . In the subset of CP class B patients, the optimal treatment is still unclear.…”

“…In the two aforementioned large‐scale clinical trials, a great majority of subjects included belonged to Child–Pugh (CP) functional class A. Several subsequent studies indicated that sorafenib‐treated patients with CP functional class B had poorer outcomes, when compared with those with CP class A . Taken together, sorafenib is not justified to be the first choice in BCLC stage C HCC patients who had CP functional class B and/or extrahepatic metastasis.…”